New Clostridium difficile pathway now in production

By: April Yarbrough, PharmD, BCPS ID/ASP Clinical Pharmacist

Children's of Alabama c. diff pathway should be in production in I-connect by November 2019. Below are a few helpful tips to know for how to navigate the order set.

What's new?

• There is a diagnostic/testing order set bundle and treatment bundle

TESTPTINPROD, EN	MERGENCY	9000677 / 1000000470	17y8m (01-20-2002)
3E-303-01			
Allergies: etoposid	e, Motrin, penicillin, Apricots, Strawberri		
equested By: 🔿 <u>M</u> e 💿	Other: CPOETest, Phys-Chemo Source: Other Alle	rgy Details	
ate:	▼ Time: ▼		
ession			
vpe: Standard	Reason:		
pe. Standard	Treason.		
anual Entry 👻	Searching for		
anuai Entiy			
	C, Diff		
		ost	
	C. Diff Diagnostic Pathway Supportive Care OS (Supportive Care C. Difficile Diagnostic Pathway OS)		
	Not indicated for patients that have received a		
	laxative within the past 24 hours, patients currently on oral Vancomycin, or patients less than 1 year of		
	age.		
	C. Difficile Infection Medication Order Set (Medication Order Set - C. Difficile Infection)		
	bindle incedoity		

Diagnostic Pathway	Treatment Pathway-Medication Order Set	
 Definition of C diff infection (CDI) and clinical symptoms (When to test) provided 	• Discontinue all unnecessary antimicrobial agents (specifically agents such as clindamycin, 3 rd generation cephalosporins and quinolones) as these may exaggerate CDI	
Risk factors for CDI (Who to test) listed	 It will be necessary to select <u>initial</u>, or <u>recurrent</u> disease, as well as <u>severity</u> to order the appropriate treatment of patients' CDI 	
 Hard stops or alerts for ordering screening No patients under 1 year of age can be tested without ID approval Formed stool will be rejected by the lab If patients have been on treatment for CDI in last 7 days or have received a laxative medication in last 48 hours 	 <u>Vancomycin (oral)</u> is now the drug of choice for CDI for patients. It will be removed from browse except for this order set since there is not other indication for PO vancomycin. Metronidazole can be considered for patients <12 years of age with no medical complexities or underlying co-mordities, and are not hospitalized with CDI related 	

	illness.
 Recommendations for ID consultation based on recurrence of disease, evaluation for FMT therapy. 	 A second or greater recurrence of CDI should prompt an ID consult for consideration of alternative medication therapy (fidaxomicin) or evaluation for fecal microbiota transplant

References:

- McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), *CID* 2018; 66(7):1–48.
- Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA), *ICHE* 2010; 31 (5): 431-455.
- Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of *Clostridium difficile* Infections. *Am J Gastroenterol 2013; 108:478-498.*